On Dec. 13, Vascepa (icosapent ethyl) became the first U.S. Food and Drug Administration (FDA)-approved medication for reducing cardiovascular risk beyond cholesterol lowering therapy in high-risk patients approved for treatment. The drug was approved specifically “as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction,…
Agency seeks information on streamlining regulations and eliminating administrative burden. Changes to the Acute Ischemic Stroke Hospitalization with Claims-Based Risk Adjustment for Stroke Severity outcomes…
The ACC joined a statement with 13 other medical specialty groups, calling on Congress and the current presidential administration to improve patient access for all…
ACC President Christopher M. Kramer, MD, FACC, testified before the U.S. House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies on…
Catch up on what’s been happening at the federal and state level with ACC Health Affairs Committee Vice Chair Jeff Marshall, MD, FACC, as he…
The re is no shortage of opportunities to learn more about advocacy topics and engage with the ACC Advocacy team at ACC.25, taking place March…
When Jae Patton, RN, MSN, CRNP, AACC, first got involved in advocacy, it was because she was required to attend ACC Legislative Conference. But she…
With your help, ACC Advocacy actively works with Congress, state legislators, and other key decision makers to transform cardiovascular care and improve heart health. However,…
The U.S. Food and Drug Administration (FDA) announced on March 3 that Philips is removing and discontinuing distribution of the Tack Endovascular System due to…
Congressional lawmakers have introduced several bipartisan bills that hold significant implications for cardiovascular care in the first six weeks of the 119th Congress. These proposals…
